Management von Krankenhausinfektionen – Ressourcenverbrauch und Kosteneffektivität

Im Krankenhaus erworbene Infektionen stellen für Patienten ein erhebliches Gesundheitsrisiko dar und führen nachweislich nicht nur zu einem deutlichen Anstieg der Morbidität und Letalität, sondern auch zu steigenden Kosten im Gesundheitswesen. Vor allem zu Infektionen mit MRSA (methicillin-resistenter Staphylococcus aureus) liegen einige Krankheitskosten-Studien aus deutschen Krankenhäusern vor, in denen die mittleren Zusatzkosten einer MRSA-Infektion mit deutlich über 5000 Euro beziffert werden. Zudem konnte gezeigt werden, dass von den Kosten einer MRSA-Infektion ein erheblicher Teil nicht durch die zusätzlichen Erstattungen gemäß dem in Deutschland verwendeten ökonomisch-medizinischen Klassifikationssystem der diagnosebezogenen Fallgruppen (DRGs) abgedeckt werden. Kosteneffektive Maßnahmen zur Infektionsprävention erscheinen angesichts dessen als eine betriebswirtschaftliche Notwendigkeit, der die Kliniken in Zeiten zunehmenden Wettbewerbs ausgesetzt sind.

Hospital-acquired infections cause a financial burden to hospitals and society through exacerbation or prolongation of illness and subsequent in-hospital treatment. Several cost-of-illness studies have been conducted at German hospitals showing that the additional cost of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) usually exceeds € 5000 per single infection. In addition, it has been shown that the in-hospital cost of such infections is largely not reimbursed under the diagnosis-related groups (DRGs) system employed in Germany. In the light of the available evidence, from the perspective of the hospitals, cost-effective interventions for the prevention of hospital-acquired infections are an economic necessity.

Key words

Hospital-acquired infections - costs - public health - MRSA (Methicillin-resistant Staphylococcus aureus) - prevention of infections

Literatur

• 1 Marwick C, Davey P. Care bundles: the holy grail of infectious risk management in hospital?.  Curr Opin Infect Dis. 2009;  22 364-369
• 2 Pronovost P, Needham D, Berenholtz S et al.. An intervention to decrease catheter-related bloodstream infections in the ICU.  N Engl J Med. 2006;  355 2725
• 3 Pronovost PJ, Berenholtz SM, Ngo K et al.. Developing and pilot testing quality indicators in the intensive care unit.  Journal of critical care. 2003;  18 145-155
• 4 Geldner G, Ruoff M, Hoffmann H-J et al.. Eine Kostenanalyse von MRSA-Infektionen auf einer operativen Intensivstation.  Anästhesiol Intensivmed Notfallmed Schmerzther. 1999;  34 409-413
• 5 Greiner W, Rasch A, Kohler D et al.. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients.  Clin Microbiol Infect. 2007;  13 264-268
• 6 Kreutzer J, Nußbaum B, Bernd L, Simank H-G. Reale Kosten der MRSA-Osteitis.  Trauma Berufskrankh. 2002;  4 344-349
• 7 Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals.  Eur J Health Econ. 2009;  10 287-297
• 8 Wernitz MH, Keck S, Swidsinski S et al.. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment.  Clin Microbiol Infect. 2005;  11 466-471
• 9 Capitano B, Leshem OA, Nightingale CH, Nicolau DP. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility.  Journal of the American Geriatrics Society. 2003;  51 10-16
• 10 Cosgrove SE, Qi Y, Kaye KS et al.. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.  Infect Control Hosp Epidemiol. 2005;  26 166-174
• 11 Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance.  Expert Rev Anti Infect Ther. 2008;  6 751-763
• 12 Reed SD, Friedman JY, Engemann JJ et al.. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia.  Infect Control Hosp Epidemiol. 2005;  26 175-183
• 13 Shorr A, Tabak Y, Gupta V et al.. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia.  Critical Care. 2006;  10
• 14 Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature.  Pharmacoeconomics. 2007;  25 751-768
• 15 Engemann JJ, Carmeli Y, Cosgrove SE et al.. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.  Clin Infect Dis. 2003;  36 592-598
• 16 Vonberg RP, Reichardt C, Behnke M et al.. Costs of nosocomial Clostridium difficile-associated diarrhoea.  J Hosp Infect. 2008;  70 15-20
• 17 Lee SY, Kotapati S, Kuti JL et al.. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.  Infect Control Hosp Epidemiol. 2006;  27 1226-1232
• 18 Schwaber MJ, Navon-Venezia S, Kaye KS et al.. Clinical and Economic Impact of Bacteremia with Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae.  Antimicrob Agents Chemother. 2006;  50 1257-1262
• 19 Wernitz MH, Swidsinski S, Weist K et al.. Effectiveness of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections.  Clin Microbiol Infect. 2005;  11 457-465
• 20 Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection.  Infect Control Hosp Epidemiol. 2009;  30 346-353
• 21 Kaier K, Frank U. Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance.  Pharmacoeconomics. 2010;  28 1123-1128

Korrespondenz